The results of studies on this topic were promising and provoked the development of further inhibitors, including anti-PD-1 (pembrolizumab and nivolumab) and anti-PD-L1 (atezolizumab and durvalumab), which are used to treat breast, gastric, and hepatocellular cancers. Here, CD274 is linked to hepatocellular carcinoma.